AIM ImmunoTech Inc.
AIMAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Ascendiant Capital | maintain | Buy | Aug 20, 2026 |
| Ascendiant Capital | maintain | Buy | Jun 1, 2026 |
| Ascendiant Capital | maintain | Buy | Apr 10, 2026 |
| Ascendiant Capital | maintain | Buy | Dec 8, 2025 |
| Ascendiant Capital | maintain | Buy | Oct 3, 2025 |
| Ascendiant Capital | maintain | Buy | Dec 10, 2024 |
| Maxim Group | maintain | Buy | Oct 22, 2024 |
| Ascendiant Capital | maintain | Buy | Sep 3, 2024 |
| Maxim Group | upgrade | Hold →Buy | Oct 10, 2019 |
| Maxim Group | downgrade | Buy →Hold | Aug 22, 2019 |
| Maxim Group | maintain | Buy | Jun 14, 2019 |
| Chardan Capital | maintain | Buy | Jan 21, 2014 |
Earnings History
Next report: Nov 16, 2026 · EPS est. $-0.09| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 7, 2026 | $-0.43 | $-0.17 | $26.0K | $100.0K |
| May 15, 2026 | $-0.69 | $-1.08 | $11.0K | $11.0K |
| Mar 27, 2026 | $-1.36 | $-0.94 | $21.0K | $100.0K |
| Nov 17, 2025 | $-1.57 | $-0.97 | $26.0K | $26.0K |
| Aug 14, 2025 | $-3.68 | $-8.00 | $25.0K | $100.0K |
| May 14, 2025 | $-5.00 | $-8.00 | $16.0K | — |
| Mar 27, 2025 | $-10.00 | $-9.00 | $45.0K | $100.0K |
| Nov 14, 2024 | $-6.00 | $-0.10 | $35.0K | $17.5K |
News
Aimia TSE: AIM reported higher third-quarter revenue as its Cortland business benefited from price increases and improving demand in several markets, while a write-down on its Clear Media investment and financing expenses contributed to a net loss.
New investor presentation outlines scientific rationale for combining Ampligen's immune-stimulating activity with daraxonrasib's targeted RAS inhibition to potentially prolong clinical benefit
CEO interview explores Ampligen's potential to extend survival and improve quality of life as AIM advances toward pivotal development
OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage of the antiviral potential of Ampligen® (rintatolimod), the Company's investigational dsRNA and highly selective TLR3 agonist immunomodulator.
Recent biotech media features focus on Ampligen's potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program Recent biotech media features focus on Ampligen's potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program
Ionic Rare Earths Ltd (ASX:IXR, OTC:IXRRF) is advancing plans to list its shares on London's AIM market in the fourth quarter of 2026 as it builds its UK presence and progresses commercialisation of its rare earth magnet recycling technology. The proposed AIM admission would complement IonicRE's existing ASX listing and is expected to broaden the company's access to UK and European investors with an interest in critical minerals and the energy transition.
Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones
Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the developer of light-activated nasal disinfection for hospital patients, has suspended trading in its shares while it raises new investment to capitalise on its clinical and commercial progress. The company is one of a growing band of growth companies to use AIM's new Capital Access Window, a voluntary pause in share trading designed to widen the pool of investors and keep the price stable during a fundraise.
1947 Oil & Gas, a newly listed oil and gas producer focused on US assets, began trading on London's AIM market on Monday with an initial valuation of about £65 million. The company issued 500 million shares at 10p each, raising £50 million through a combination of shares issued to the vendor of Renaissance Offshore and a placing with new investors.
1947 Oil & Gas PLC (AIM:1947) begins trading on AIM today, with shares marked at a premium price and ambitions to lift production from its newly acquired US Gulf of America assets by around 50% over the next two years. In its London IPO, the junior oil and gas raised roughly £30 million at 10p a share to help fund its US$65 million acquisition of Houston-based Renaissance Offshore.
Digitalbox PLC (AIM:DBOX, FRA:RLXB), the mobile-first digital media group behind The Daily Mash and The Tab, believes the upheaval sweeping digital media presents significant opportunities for nimble players, and says a strong balance sheet leaves it well placed to seize them. The AIM-listed company, which ended June with £2 million of cash, is pressing ahead with a major expansion built around original video and online creators.
Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer Survival data highlighted in accompanying chart show Ampligen-associated median overall survival of 34.8 months in a selected pancreatic patient population versus 12.5 months in historical controls OCALA, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a letter to stockholders from Chief Executive Officer Thomas Equels a…
Shore Capital has welcomed the latest step forward in Coiled Therapeutics' (AIM:COIL, OTCQB:COTXF) cancer drug trial, reiterating its support for the AIM-listed group. The broker was responding to Monday's news that Coiled had enrolled six patients across two dose groups testing a reformulated version of its lead drug, AO-252.
Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) has enrolled the first patients into two dose groups testing a reformulated version of its experimental cancer drug. The AIM-listed oncology group said it had signed up three patients each to a twice-daily 120mg cohort and a once-daily 160mg cohort of AO-252, its lead treatment.
KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF, FRA:KMSA), the AIM-listed explorer developing the Tulu Kapi gold project in Ethiopia, said all employees affected by last week's security incident have been accounted for, with no further casualties. One employee was killed and Kefi suspended development at the site after the attack on 4 September.
Sintana Energy Inc (TSX-V:SEI, OTCQB:SEUSF, FRA:3ZX1, AIM:SEI) has signed definitive agreements for its proposed entry into Angola's Block KON-16, securing an indirect 5% participating interest as the partners work towards a pre-salt exploration well in 2027. The company will pay US$2.5 million for the interest, including US$500,000 already paid to Corcel PLC (AIM:CRCL, FRA:RM4B) and a further US$2 million due on completion.
Company continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen's potential to reshape the tumor microenvironment and enhance checkpoint inhibition
Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the AIM-listed company behind light-activated antimicrobial therapies, has agreed a partnership with Hospital Ángeles, Mexico's largest private healthcare network, to pilot its Steriwave nasal photodisinfection treatment. The multi-centre pilot follows positive results from Ondine's phase III trial of 5,188 patients across Canadian and US hospitals, which showed a 40% reduction in post-surgical infection rates compared with standard care.
Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom
OCALA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office has granted a patent covering the use of the Company's drug Ampligen in combination with the PD-1 checkpoint inhibitor pembrolizumab for the treatment of cancer.